16 news items
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY
14 May 24
® (tafasitamab)] is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights
TD Cowen Maintains Buy on Incyte, Lowers Price Target to $80
INCY
1 May 24
TD Cowen analyst Marc Frahm maintains Incyte (NASDAQ:INCY) with a Buy and lowers the price target from $88 to $80.
Truist Securities Reiterates Buy on Incyte, Lowers Price Target to $83
INCY
1 May 24
Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:INCY) with a Buy and lowers the price target from $84 to $83.
BMO Capital Maintains Market Perform on Incyte, Lowers Price Target to $52
INCY
1 May 24
BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and lowers the price target from $56 to $52.
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY
30 Apr 24
into an asset purchase agreement with MorphoSys AG which gave Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting
a41m586e 98
INCY
24 Apr 24
Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $92 to $84.
915icgr6y3ex9xnyh3g3a
INCY
MOR
23 Apr 24
Blair highlights the intriguing potential of the MRGPRX2 target. Initial data in chronic inducible urticaria suggests that EP262 complements
ze6ezc1lpdkh3lru30rfv55ckucy4t7mocg y35mrik0o88u8qk7app
INCY
23 Apr 24
0
0
In the assessment of 12-month price targets
h3d pnh32nksdrs55ny
INCY
25 Mar 24
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.
m52f 7y4l0hrirhkkg40ixk6
INCY
13 Mar 24
B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $69 to $67.
z3zyq4a8op8haypgwr1np0q6deiwbipkfgv8jujwnf2nvih ge
INCY
12 Mar 24
Stifel analyst Stephen Willey reiterates Incyte (NASDAQ:INCY) with a Hold and maintains $68 price target.
3lgxn4vdhdniynbi4dbbgv7j5bkg4 ota9ba09y08b
INCY
12 Mar 24
0
0
The 12-month price targets assessed by analysts reveal
5rj32xr0mhv1u3zxie11mmywgmpyxfiqd7kj38hu75
INCY
12 Mar 24
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.
2d25vo 2cbr5ljz40s85cgf3h6m31g6ktpjmb1kvrivxsdst03ryl8yl7ai6
INCY
29 Feb 24
. About Tafasitamab (Minjuvi®) Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting
tklyxex6yoyj7563l37l
INCY
SNDX
27 Feb 24
antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function
jewlbkvwkfuicfx3pqw9ryd0
INCY
23 Feb 24
Jefferies analyst Kelly Shi initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $81.
- Prev
- 1
- Next